ZCUBE-ZAMBON-RESEARCH
28.2.2024 14:01:33 CET | Business Wire | Press release
Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences. Starting this year, the program will focus on the femtech sector and will feature a new format. The initiative, one of the first internationally in terms of focus and invested capital, invites startups and entrepreneurial ideas aimed at developing products and services to address major medical needs and improve women's health and well-being. The targeted therapeutic areas include gynecology, cardiovascular health, oncology, sexual health, endocrinology, gastroenterology, nutrition, autoimmune disorders, mental health, neurology, reproductive health, and more.
The Call for application will open on Friday, March 8, 2024, on the International Women's Day, and will remain open until June 16. At the end of the selection process, up to 5 startups will be identified to receive an investment of €100,000 each, through a SAFE (Simple Agreement for Future Equity) agreement and will have access to a training and mentoring program delivered by experts in the fields of investments, business development, venture capital, intellectual property, regulatory affairs, and market access.
Startups with the highest potential will also have the opportunity to build a partnership with the Zambon group, accelerating their market access phase and commercial positioning on a global scale.
“We are eager to launch the fifth edition of Open Accelerator; we are excited to discover which companies can bring innovative solutions to change the Life Sciences and women’s health sector. The choice to dedicate the 2024 edition to the femtech sector is deliberate: working in unexplored areas can contribute to creating benefits for the global economy. As highlighted by recent studies, bridging this gender gap is essential” - said Giovanni Magnaghi, President of Zcube and Chief Financial Officer of Zambon – “Since 2016, Open Accelerator has allowed us to offer direct access to capital and expertise to new and promising entrepreneurial ideas, thanks to the collaboration with prominent partners participating in the open innovation ecosystem at our scientific campus, OpenZone, where part of the program is hosted”.
The previous four editions of the program selected 46 startups from 23 countries, 8 of which have received up to €100,000 each in seed investment. The winner of the Distinction Award during the last edition of Open Accelerator comes from the femtech sector: Hyivy Health, a Canadian startup developing a medical device for pelvic floor rehabilitation. Founded in 2019 by Canadian entrepreneur Rachel Bartholomew following a diagnosis of cervical cancer, Hyivy Health aims to improve the standard of care for both patients and physicians through a holistic approach. Bartholomew, CEO of Hyivy Health, commented on the launch of the new edition of Open Accelerator: “It is a turning point for the industry. Open Accelerator is one of the first programs to enter this field with resources and real opportunities for femtech startups on a global level”.
“Open Accelerator values the experience of Zcube and best expresses our vision of Zambon as an open company, where open innovation serves as a lever for cultural and entrepreneurial growth for both us and the entire system” - commented Elena Zambon, President of Zambon and creator of Open Accelerator – “Women's health is a fundamental focus for Zambon and a central issue in international health agendas: supporting these entities and helping them bringing their innovative entrepreneurial ideas to market is an additional effort by our group to innovate cure and care to make patients’ lives better”.
Coordinating Open Accelerator will be a team of professionals experienced in Life Sciences and Venture Capital including Federica Destro, External Innovation & Community manager at Zcube, Vittoria Pavoncello, Technology Scouting & Investment Specialist at Zcube, Michele Gaiotto, CEO of HTH and Advisor to Zcube, and Marco Gullà, Investment Associate at HTH.
For more information about the program, visit www.openaccelerator.it/
For more information about Zcube, visit www.zambon.com/en/innovation/zcube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226030549/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
